Satio and Nanowear have entered a partnership agreement aimed at progressing home-based diagnostic and therapeutic care that is said to be patient-friendly.
This partnership is set to integrate the AI-based nanotechnology biomarker diagnostic platform of Nanowear with Satio’s blood draw diagnostics and drug delivery patches.
Go deeper with GlobalData
Nanowear focuses on transforming home-based cardiometabolic healthcare with its FDA-approved cloth nanotechnology and AI diagnostics, SimpleSense, which offers cardiometabolic evaluation.
The platform claims to gather more than 85 clinically validated haemodynamic and cardiopulmonary biomarkers, providing a continuous health picture while the individual is at home.
Satio noted that recently, its telemedicine initiative featuring remote-controlled drug delivery was acknowledged as the inaugural project to reach completion under the Advanced Research Development Agency for Health (ARPA-H) Challenge programme.
The company is focusing on decentralised healthcare with its adhesive patch technology, designed to streamline clinical workflows and bring blood-based diagnostics and drug delivery out of traditional healthcare settings and into the home.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis collaboration is set to expedite the decentralisation efforts of Satio through information capture and analytics.
Both companies are exploring several pathways for transforming home-based diagnostics and care.
The companies noted that an initiative aims to combine SatioDot and SatioDraw blood collection patches with Nanowear’s SimpleSense technology. This combo integrates genotype and blood biomarkers with cardiometabolic physiological data, all accessible through one digital application.
The biomarkers from SimpleSense will also be incorporated into the telehealth drug delivery system of SatioRx.
Moreover, the companies plan to co-promote their technological and combined offerings to prime stakeholders.
Satio founder and chairman Namal Nawana said: “We are excited about the opportunities to merge in vitro and in vivo results and to enhance chronic disease, cardiometabolic, and cancer drug delivery.
“This partnership will help ensure the patient’s ease of mind and the clinician’s decision-making are strengthened, not thrown into doubt.”
In 2023, Satio secured a contract from the Biomedical Advanced Research and Development Authority (BARDA) for the development of a patch-based diagnostic for ebolavirus.
